Literature DB >> 12904413

Evaluation of susceptibility of human herpesvirus 8 to antiviral drugs by quantitative real-time PCR.

Yan Sergerie1, Guy Boivin.   

Abstract

A new in vitro system based on real-time PCR was developed for evaluation of human herpesvirus 8 susceptibility to antiviral agents. Cidofovir had the greatest inhibitory activity against HHV-8 (50% inhibitory concentration [IC(50)], 0.43 microM) followed by ganciclovir (2.61 microM), adefovir (18.00 microM), acyclovir (31.00 microM), and foscarnet (34.15 microM). The potential therapeutic efficacy for HHV-8 (i.e., peak serum drug level/IC(50)) is highest for cidofovir (167) and foscarnet (22).

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12904413      PMCID： PMC179795          DOI： 10.1128/JCM.41.8.3897-3900.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  24 in total

1.  Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma.

Authors:  L P Jacobson; F J Jenkins; G Springer; A Muñoz; K V Shah; J Phair; Z Zhang; H Armenian
Journal:  J Infect Dis       Date:  2000-05-26       Impact factor: 5.226

2.  Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis.

Authors:  G Boivin; C Gilbert; A Gaudreau; I Greenfield; R Sudlow; N A Roberts
Journal:  J Infect Dis       Date:  2001-12-03       Impact factor: 5.226

3.  Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.

Authors:  F Brown; L Banken; K Saywell; I Arum
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

Review 4.  Drugs five years later: acyclovir.

Authors:  D I Dorsky; C S Crumpacker
Journal:  Ann Intern Med       Date:  1987-12       Impact factor: 25.391

5.  A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

Authors:  Daniel F Martin; Juan Sierra-Madero; Sharon Walmsley; Richard A Wolitz; Katherine Macey; Panos Georgiou; Charles A Robinson; Mary Jean Stempien
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

6.  Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.

Authors:  F Aweeka; J Gambertoglio; J Mills; M A Jacobson
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

7.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

8.  Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease.

Authors:  Guy Boivin; Stéphanie Côté; Nathalie Cloutier; Yacine Abed; Michelle Maguigad; Jean-Pierre Routy
Journal:  J Med Virol       Date:  2002-11       Impact factor: 2.327

9.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.

Authors:  Y Chang; E Cesarman; M S Pessin; F Lee; J Culpepper; D M Knowles; P S Moore
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

Review 10.  Valaciclovir (BW256U87): the L-valyl ester of acyclovir.

Authors:  M A Jacobson
Journal:  J Med Virol       Date:  1993       Impact factor: 2.327
View more
  14 in total

1.  Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus.

Authors:  Yan-Jin Zhang; Rheba S Bonaparte; Deendayal Patel; David A Stein; Patrick L Iversen
Journal:  Mol Cancer Ther       Date:  2008-03       Impact factor: 6.261

2.  De novo and recurrent Kaposi's Sarcoma after renal transplantation in two patients taking everolimus.

Authors:  G Vergoulas; Gr Miserlis; M Leontsini; V Papanikolaou; D Takoudas
Journal:  Hippokratia       Date:  2008-07       Impact factor: 0.471

3.  Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.

Authors:  Yan-Jin Zhang; Deendayal Patel; Yuchen Nan; Sumin Fan
Journal:  Antivir Ther       Date:  2011

4.  Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses.

Authors:  Natacha Coen; Sophie Duraffour; Dimitri Topalis; Robert Snoeck; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

5.  Evaluation of Epstein-Barr virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays.

Authors:  Lotfi Bounaadja; Jocelyne Piret; Nathalie Goyette; Guy Boivin
Journal:  J Clin Microbiol       Date:  2013-01-16       Impact factor: 5.948

6.  Calibration technologies for correct determination of Epstein-Barr Virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays.

Authors:  Francesco Broccolo; Paolo Lusso; Mauro Malnati
Journal:  J Clin Microbiol       Date:  2013-06       Impact factor: 5.948

7.  Reply to "Calibration technologies for correct determination of Epstein-Barr Virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays".

Authors:  Lotfi Bounaadja; Jocelyne Piret; Nathalie Goyette; Guy Boivin
Journal:  J Clin Microbiol       Date:  2013-06       Impact factor: 5.948

8.  Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers.

Authors:  Yan-Jin Zhang; Kai-Yu Wang; David A Stein; Deendayal Patel; Rheba Watkins; Hong M Moulton; Patrick L Iversen; David O Matson
Journal:  Antiviral Res       Date:  2006-06-14       Impact factor: 5.970

Review 9.  KSHV targeted therapy: an update on inhibitors of viral lytic replication.

Authors:  Natacha Coen; Sophie Duraffour; Robert Snoeck; Graciela Andrei
Journal:  Viruses       Date:  2014-11-24       Impact factor: 5.048

Review 10.  Viral Oncology: Molecular Biology and Pathogenesis.

Authors:  Uyen Ngoc Mui; Christopher T Haley; Stephen K Tyring
Journal:  J Clin Med       Date:  2017-11-29       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.